220 related articles for article (PubMed ID: 33609419)
1. Impact of diabetes on promoting the growth of breast cancer.
Chou PC; Choi HH; Huang Y; Fuentes-Mattei E; Velazquez-Torres G; Zhang F; Phan L; Lee J; Shi Y; Bankson JA; Wu Y; Wang H; Zhao R; Yeung SJ; Lee MH
Cancer Commun (Lond); 2021 May; 41(5):414-431. PubMed ID: 33609419
[TBL] [Abstract][Full Text] [Related]
2. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors.
Cleary MP; Juneja SC; Phillips FC; Hu X; Grande JP; Maihle NJ
Exp Biol Med (Maywood); 2004 Feb; 229(2):182-93. PubMed ID: 14734797
[TBL] [Abstract][Full Text] [Related]
3. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
Wang QF; Ding H; Liu BR; Zhang K
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth.
Velazquez-Torres G; Fuentes-Mattei E; Choi HH; Yeung SJ; Meng X; Lee MH
Gastroenterol Rep (Oxf); 2020 Aug; 8(4):261-276. PubMed ID: 32843973
[TBL] [Abstract][Full Text] [Related]
5. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.
Zhu P; Davis M; Blackwelder AJ; Bachman N; Liu B; Edgerton S; Williams LL; Thor AD; Yang X
Cancer Prev Res (Phila); 2014 Feb; 7(2):199-210. PubMed ID: 24322659
[TBL] [Abstract][Full Text] [Related]
6. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
[TBL] [Abstract][Full Text] [Related]
7. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
He X; Esteva FJ; Ensor J; Hortobagyi GN; Lee MH; Yeung SC
Ann Oncol; 2012 Jul; 23(7):1771-80. PubMed ID: 22112968
[TBL] [Abstract][Full Text] [Related]
8. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
10. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
11. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload.
Altamura S; Müdder K; Schlotterer A; Fleming T; Heidenreich E; Qiu R; Hammes HP; Nawroth P; Muckenthaler MU
Mol Metab; 2021 Sep; 51():101235. PubMed ID: 33872860
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.
Fierz Y; Novosyadlyy R; Vijayakumar A; Yakar S; LeRoith D
Endocr Relat Cancer; 2010 Dec; 17(4):941-51. PubMed ID: 20801951
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
Fry EA; Taneja P; Inoue K
Int J Cancer; 2017 Feb; 140(3):495-503. PubMed ID: 27553713
[TBL] [Abstract][Full Text] [Related]
14. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
Fuentes-Mattei E; Velazquez-Torres G; Phan L; Zhang F; Chou PC; Shin JH; Choi HH; Chen JS; Zhao R; Chen J; Gully C; Carlock C; Qi Y; Zhang Y; Wu Y; Esteva FJ; Luo Y; McKeehan WL; Ensor J; Hortobagyi GN; Pusztai L; Fraser Symmans W; Lee MH; Yeung SC
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957076
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.
So JY; Wahler JE; Yoon T; Smolarek AK; Lin Y; Shih WJ; Maehr H; Uskokovic M; Liby KT; Sporn MB; Suh N
Cancer Prev Res (Phila); 2013 Sep; 6(9):959-70. PubMed ID: 23856074
[TBL] [Abstract][Full Text] [Related]
16. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
Young CD; Nolte EC; Lewis A; Serkova NJ; Anderson SM
Breast Cancer Res; 2008; 10(4):R70. PubMed ID: 18700973
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.
Wilson KD; Li Z; Wagner R; Yue P; Tsao P; Nestorova G; Huang M; Hirschberg DL; Yock PG; Quertermous T; Wu JC
PLoS One; 2008 Jul; 3(7):e2609. PubMed ID: 18648539
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
19. Adipose-derived stromal cells reverse insulin resistance through inhibition of M1 expression in a type 2 diabetes mellitus mouse model.
Chen LW; Chen PH; Tang CH; Yen JH
Stem Cell Res Ther; 2022 Jul; 13(1):357. PubMed ID: 35883204
[TBL] [Abstract][Full Text] [Related]
20. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
